ArticleAmerican journal of translational research2025
Circulating serum exosomes 5'Leader ArgTCG and 3'tRF SerGCT combined with tumor biomarkers as non-invasive diagnostic and monitoring indicators for colorectal cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesColorectal cancer (CRC) has one of the highest incidence and mortality rates among cancers, particularly concerning the rates of diagnosis. Serum exosomes (Exos) are crucial mediators for the intercellular transmission of genetic information. These vesicles contain various tRNA-derived fragments (tRFs) that play a role in the noncoding regulation of tumor genes. Consequently, they are anticipated to become valuable non-invasive diagnostic and predictive biomarkers for CRC.
methodsAt the Affiliated Taian City Central Hospital of Qingdao University, we isolated and extracted serum Exos from 201 healthy donors and 205 patients with CRC. To measure Exo physical morphology, we utilized qNano, transmission electron microscopy, and a particle size analyzer. Western blotting was conducted to confirm the expression of surface and nuclear proteins in the Exos. Gene chips were employed to screen for differentially expressed tRF RNAs. The quantitative PCR technology was deployed to ascertain 5'Leader-ArgTCG and 3'tRF-SerGCT differential expression. CRC diagnostic efficiency was assessed utilizing the area under the curve.
resultsWe compared 5'Leader-ArgTCG and 3'tRF-SerGCT expression in 205 patients with CRC and 201 healthy donors. Among them, 5'Leader-ArgTCG was significantly downregulated, while 3'tRF-SerGCT was significantly upregulated. The diagnostic efficiency of predicting 5'Leader-ArgTCG and 3'tRF-SerGCT in serum Exos using survival curves was 0.659 and 0.659, respectively. Meanwhile, the diagnostic efficiency of combining the two tumor markers was 0.954.
conclusionSerum Exos 5'Leader-ArgTCG and 3'tRF-SerGCT were differentially expressed in patients with CRC. Combining these two tumor markers may serve as a predictive indicator for the non-invasive diagnosis of CRC, demonstrating notable statistical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.